Qualigen therapeutics regains compliance with nasdaq minimum bid price rule

Carlsbad, calif., dec. 12, 2022 (globe newswire) -- qualigen therapeutics, inc. (“qualigen” or “the company,” nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, while also commercializing diagnostics, today announces that it has received written notice from the listing qualifications department of the nasdaq stock market llc (“nasdaq”) informing the company that it has regained compliance with nasdaq's minimum bid price requirement under listing rule 5550(a)(2) for continued listing on the nasdaq capital market. the letter noted that as a result of the closing bid price of the company's common stock having been at least $1.00 per share for a minimum of 10 consecutive business days, the company has regained compliance with listing rule 5550(a)(2) and the matter is now closed.
QLGN Ratings Summary
QLGN Quant Ranking